David A. Schwartz

David A. Schwartz

University of Colorado Denver

H-index: 114

North America-United States

About David A. Schwartz

David A. Schwartz, With an exceptional h-index of 114 and a recent h-index of 67 (since 2020), a distinguished researcher at University of Colorado Denver, specializes in the field of innate immunity, pulmonary fibrosis, asthma, genetics, epigenetics.

His recent articles reflect a diverse array of research interests and contributions to the field:

MUC5B Promoter Variant Drives the Protein Signature in Early Lung Fibrosis

Long Non-coding RNA in IPF: Regulatory Players in Lung Fibrosis

In Idiopathic Pulmonary Fibrosis (IPF), MUC5B Promoter Variant Rs35705950 Correlates With DNA Hypomethylation in the Gene Promoter Area

The Spectrum and Pathogenicity of Clonogenic Basal Cells in Lung Disease

The MUC5B Genotype and Other Common Variants Are Associated With Computational Imaging Features of Usual Interstitial Pneumonia Pattern Among Patients With Idiopathic Pulmonary …

Associations of COPD and Related Outcomes With COVID-19 Hospitalization or Death: The C4R, Copdgene, and Spiromics Studies

Orthologous rs35705950 MUC5B Promoter Locus in Mice May Provide Insights into MUC5B-driven Lung Fibrosis in Humans

Synergistic Effects of Nintedanib With BCL-2 Inhibition to Drive Pro-fibrotic Fibroblast Apoptosis

David A. Schwartz Information

University

Position

Professor of Medicine and Immunology

Citations(all)

53281

Citations(since 2020)

17410

Cited By

42539

hIndex(all)

114

hIndex(since 2020)

67

i10Index(all)

371

i10Index(since 2020)

240

Email

University Profile Page

Google Scholar

David A. Schwartz Skills & Research Interests

innate immunity

pulmonary fibrosis

asthma

genetics

epigenetics

Top articles of David A. Schwartz

MUC5B Promoter Variant Drives the Protein Signature in Early Lung Fibrosis

2024/5

Long Non-coding RNA in IPF: Regulatory Players in Lung Fibrosis

2024/5

In Idiopathic Pulmonary Fibrosis (IPF), MUC5B Promoter Variant Rs35705950 Correlates With DNA Hypomethylation in the Gene Promoter Area

2024/5

The Spectrum and Pathogenicity of Clonogenic Basal Cells in Lung Disease

2024/5

The MUC5B Genotype and Other Common Variants Are Associated With Computational Imaging Features of Usual Interstitial Pneumonia Pattern Among Patients With Idiopathic Pulmonary …

2024/5

Associations of COPD and Related Outcomes With COVID-19 Hospitalization or Death: The C4R, Copdgene, and Spiromics Studies

2024/5

Orthologous rs35705950 MUC5B Promoter Locus in Mice May Provide Insights into MUC5B-driven Lung Fibrosis in Humans

2024/5

Synergistic Effects of Nintedanib With BCL-2 Inhibition to Drive Pro-fibrotic Fibroblast Apoptosis

2024/5

Genetics and Genomics of Pulmonary Fibrosis: Charting the Molecular Landscape and Shaping Precision Medicine

American Journal of Respiratory and Critical Care Medicine

2024/4/4

Fibrosis model and methods of use thereof

2024/3/19

Demographic and Clinical Factors Associated With SARS-CoV-2 Spike 1 Antibody Response Among Vaccinated US Adults: the C4R Study

Nature Communications

2024/2/19

Pulmonary Fibrosis Stakeholder Summit: A Joint NHLBI, Three Lakes Foundation, and Pulmonary Fibrosis Foundation Workshop Report

American Journal of Respiratory and Critical Care Medicine

2024/2/15

Genetic Locus Associated With Bleomycin Induced Lung Fibrosis in Mice

2024/5

Toll-Like-Receptor 5 protects against pulmonary fibrosis by reducing lung dysbiosis

2022/5

A Novel Basal Cell Variant Committed to Honeycomb Cysts in IPF Across MUC5B Haplotypes

2024/5

Movement of Epithelial Cells in Idiopathic Pulmonary Fibrosis (IPF) Is Associated With the Extent of Lung Fibrosis

2024/5

Associations of Pre-pandemic Spirometry With COVID-19 Hospitalization or Death: The Collaborative Cohort of Cohorts for COVID-19 Research (C4R) Study

2024/5

Muc5b Overexpression and Aging Results in Lung Fibrosis in Mice

2024/5

See List of Professors in David A. Schwartz University(University of Colorado Denver)

Co-Authors

academic-engine